Candel Therapeutics Stock Discussion

$Candel Therapeutics (CADL.US)$
Let's Get 5.+

$Candel Therapeutics (CADL.US)$
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
Candel Therapeutics announced preclinical results for CAN-3110 in melanoma models, showing potential expansion beyond high-grade glioma treatment. CAN-3110, a first-in-class HSV-1 oncolytic viral immunotherapy, demonstrated potent antitumor activity in both in vitro human cel...

$Candel Therapeutics (CADL.US)$
Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)
Candel Therapeutics presented three key developments at the 16th Annual International Oncolytic Virotherapy Conference. The highlights include promising data from the CAN-3110 phase 1b trial in recurrent high-grade glioma, showing 3 out of 6 patients surviving over one year after treatment. The trial demonstrated improved survi...

$Candel Therapeutics (CADL.US)$
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
Candel Therapeutics (Nasdaq: CADL), a clinical-stage biopharmaceutical company developing multimodal biological immunotherapies for cancer, announced its upcoming presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting. The event will take place from November 6-10, 2024, in Houston, Texas, and virtually.
The c...